{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:44Z","timestamp":1781636204362,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are characterized by persistent airway inflammation and airflow limitation. Measuring airway inflammation may be of value both in research and clinical practice. Calprotectin, a protein associated with neutrophil activation, serves as a potential biomarker for airway inflammation. This study evaluates the performance of a particle enhanced turbidimetric immunoassay (PETIA) for measuring calprotectin in sputum samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty sputum samples from unique patients were collected at the Department of Clinical Microbiology in Lund, Sweden and treated with dithiothreitol (DTT) before analysis. Calprotectin levels were measured using a PETIA on an automated turbidimetric analysis system (Atellica CH 930 Analyzer). The 30 samples were analyzed in triplicate the day of sample collection (Day 0), after storage at 4\u00a0\u00b0C for two to four days (Day 2\u20134), and after six to seven days (Day 6\u20137). An additional aliquot from each sample was stored at -20\u00a0\u00b0C and analyzed after 41 to 58 days (Day 41\u201358). Precision, accuracy, and stability of the assay were assessed. Precision was evaluated using pooled- and individual sputum samples while accuracy was determined through spiking studies and dilution linearity. Stability was tested by comparing calprotectin levels Day 2\u20134, Day 6\u20137 and Day 41\u201358 with Day 0, respectively. Instability equations were calculated for samples stored at 4\u00a0\u00b0C and at -20\u00a0\u00b0C, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three different pools were each analyzed 25 times during five days. The coefficient of variation (CV) for the calprotectin concentration was below 3% for all three. Considering precision based on individual samples, 90% of 120 triplicates had a CV below 7%. These figures indicate an acceptable precision. The spiking and dilution studies showed that measured calprotectin concentrations matched expected levels, with deviations below 10%. Calprotectin concentrations Day 2\u20134, Day 6\u20137 and Day 41\u201358 did not significantly differ from Day 0, and the slope of the instability equations did not significantly differ from 0. It implies that calprotectin concentration can be measured in DTT treated sputum stored for up to one week at 4\u00a0\u00b0C and up to two months at -20\u00a0\u00b0C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The evaluated PETIA, running on an automated system, provides a promising method for measuring calprotectin in sputum, supporting its potential use in both clinical and research applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04195-1","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:33:31Z","timestamp":1771677211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of a Particle Enhanced Turbidimetric Immunoassay (PETIA) for detecting calprotectin in sputum samples"],"prefix":"10.1186","volume":"26","author":[{"given":"Magnus","family":"F\u00f6rnvik Jonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My","family":"Elt\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgny","family":"Sunnerhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Al-Jammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Paulsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"4195_CR1","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMoa032158","volume":"350","author":"JC Hogg","year":"2004","unstructured":"Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645\u201353.","journal-title":"N Engl J Med"},{"key":"4195_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.chest.2021.10.049","volume":"161","author":"CR Esther Jr","year":"2022","unstructured":"Esther CR Jr, O\u2019Neal WK, Anderson WH, Kesimer M, Ceppe A, Doerschuk CM, et al. Identification of sputum biomarkers predictive of pulmonary exacerbations in COPD. Chest. 2022;161:1239\u201349.","journal-title":"Chest"},{"key":"4195_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1513\/pats.200703-044BR","volume":"4","author":"SD Sagel","year":"2007","unstructured":"Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc. 2007;4:406\u201317.","journal-title":"Proc Am Thorac Soc"},{"key":"4195_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1164\/rccm.201810-1860SO","volume":"199","author":"RA Stockley","year":"2019","unstructured":"Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am J Respir Crit Care Med. 2019;199:1195\u2013204.","journal-title":"Am J Respir Crit Care Med"},{"key":"4195_CR5","doi-asserted-by":"publisher","first-page":"240229","DOI":"10.1183\/16000617.0229-2024","volume":"34","author":"E Gromelsky Ljungcrantz","year":"2025","unstructured":"Gromelsky Ljungcrantz E, Askman S, Sj\u00f6vall F, Paulsson M. Biomarkers in lower respiratory tract samples in the diagnosis of ventilator-associated pneumonia: a systematic review. Eur Respir Rev. 2025;34:240229.","journal-title":"Eur Respir Rev"},{"key":"4195_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/ajcp\/84.1.24","volume":"84","author":"I Dale","year":"1985","unstructured":"Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol. 1985;84:24\u201334.","journal-title":"Am J Clin Pathol"},{"key":"4195_CR7","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","volume":"70","author":"A Jukic","year":"2021","unstructured":"Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021;70:1978\u201388.","journal-title":"Gut"},{"key":"4195_CR8","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.jbc.2023.102952","volume":"299","author":"M Polakowska","year":"2023","unstructured":"Polakowska M, Steczkiewicz K, Szczepanowski RH, Wys\u0142ouch-Cieszy\u0144ska A. Toward an understanding of the conformational plasticity of S100A8 and S100A9 Ca2+-binding proteins. J Biol Chem. 2023;299:102952.","journal-title":"J Biol Chem"},{"key":"4195_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8\/A9 in Inflammation. Front Immunol. 2018;9:1298.","journal-title":"Front Immunol"},{"key":"4195_CR10","doi-asserted-by":"publisher","first-page":"1045636","DOI":"10.3389\/fcimb.2022.1045636","volume":"12","author":"RY Gao","year":"2022","unstructured":"Gao RY, Jia HM, Han YZ, Qian BS, You P, Zhang XK, et al. Calprotectin as a diagnostic marker for sepsis: a meta-analysis. Front Cell Infect Microbiol. 2022;12:1045636.","journal-title":"Front Cell Infect Microbiol"},{"key":"4195_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","volume":"22","author":"M Jarlborg","year":"2020","unstructured":"Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22:105.","journal-title":"Arthritis Res Ther"},{"key":"4195_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jcf.2010.01.005","volume":"9","author":"RD Gray","year":"2010","unstructured":"Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010;9:193\u20138.","journal-title":"J Cyst Fibros"},{"key":"4195_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.anai.2013.06.028","volume":"111","author":"TH Lee","year":"2013","unstructured":"Lee TH, Jang AS, Park JS, Kim TH, Choi YS, Shin HR, et al. Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflammation in severe uncontrolled asthma. Ann Allergy Asthma Immunol. 2013;111:268\u201375.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4195_CR14","doi-asserted-by":"publisher","first-page":"19241","DOI":"10.1038\/s41598-019-55502-2","volume":"9","author":"X Huang","year":"2019","unstructured":"Huang X, Tan X, Liang Y, Hou C, Qu D, Li M, Huang Q, et al. Differential DAMP release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients. Sci Rep. 2019;9:19241.","journal-title":"Sci Rep"},{"key":"4195_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1164\/rccm.200703-409OC","volume":"178","author":"RD Gray","year":"2008","unstructured":"Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med. 2008;178:444\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"4195_CR16","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3390\/biomedicines10081949","volume":"10","author":"A Mulvanny","year":"2022","unstructured":"Mulvanny A, Pattwell C, Beech A, Southworth T, Singh D. Validation of sputum biomarker immunoassays and cytokine expression profiles in COPD. Biomedicines. 2022;10:1949.","journal-title":"Biomedicines"},{"key":"4195_CR17","unstructured":"IFU Gentian Calprotectin Reagent. REF1201, 7704\u2013ven04."},{"key":"4195_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1465-9921-11-41","volume":"11","author":"SD Aaron","year":"2010","unstructured":"Aaron SD, Vandemheen KL, Ramsay T, Zhang C, Avnur Z, Nikolcheva T, Quinn A. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res. 2010;11:41.","journal-title":"Respir Res"},{"key":"4195_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jpba.2011.03.033","volume":"55","author":"MA Valentin","year":"2011","unstructured":"Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal. 2011;55:869\u201377.","journal-title":"J Pharm Biomed Anal"},{"key":"4195_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1515\/cclm-2020-0061","volume":"59","author":"M Cornes","year":"2020","unstructured":"Cornes M, Simundic AM, Cadamuro J, Costelloe SJ, Baird G, Kristensen GBB, et al. CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE). Clin Chem Lab Med. 2020;59:59\u201369.","journal-title":"Clin Chem Lab Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04195-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04195-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04195-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:38:19Z","timestamp":1781635099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04195-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04195-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Swedish Ethical Review Authority (Dnr 2024-03624-01).Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}